°®¶¹´«Ã½

Listed Company Name:°®¶¹´«Ã½.
Representative:Haruo Naito
President & CEO
Securities Code:4523
Stock Exchange Listing:First Section of the Tokyo
Stock Exchange
Inquiries:Sayoko Sasaki
Vice President,
Corporate Affairs
Phone 81-3-3817-5120

°®¶¹´«Ã½. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that, at a meeting of its Board of Directors held earlier today, it resolved to voluntarily adopt International Financial Reporting Standards (IFRS) for consolidated financial statements in lieu of the Japanese Generally Accepted Accounting Principles (J-GAAP) it has currently adopted. Disclosure of consolidated financial statements under IFRS is scheduled to be implemented across the Eisai Group starting from the first quarter of the fiscal year ending March 31, 2015.

In line with its human health care (hhc) philosophy, the Eisai Group continues to conduct its pharmaceuticals business operations in diverse markets and regions, including Japan, the Americas, Europe and Asia. In this light, Eisai has resolved to voluntarily adopt IFRS across the Eisai Group to enable readier comparison and disclosure of financial information on an international basis and thereby increase convenience to various shareholders, investors and other stakeholders both in Japan and abroad.

The disclosure schedule for the Eisai Group’s transition to IFRS is as follows (tentative):

***